Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients

We-Yu Kao, MD, Yee Chao, MD, PhD, Chun-Chao Chang, MD, Chung-Pin Li, MD, PhD, Chien-Wei Su, MD, PhD, Teh-Ja Huo, MD, Yi-Hsiang Huang, MD, PhD, Yu-Jia Chang, PhD, Han-Chieh Lin, MD, and Jaw-Ching Wu, MD, PhD

Abstract: The prognostic implication of Barcelona Clinic Liver Cancer (BCLC) substages in Asian patients with hepatocellular carcinoma (HCC) is still obscure.

The aim to this study is to compare the prognoses among HCC patients in different substages of the BCLC stage 0 and A.

We enrolled 1265 treatment-naive HCC patients with BCLC stage 0 or A from 2007 to 2014. Factors in terms of prognoses were analyzed by multivariate analysis.

There were 184, 446, 271, 92, and 272 patients in substage 0, A1, A2, A3, and A4, respectively. After a median follow-up period of 21.0 months, patients in stages 0 and A1 had comparable prognoses (P = 0.136). Both of them had significantly higher overall survival rates than those in stages A2–A4 (all P < 0.001). Multivariate analysis revealed that the factors associated with mortality were serum albumin ≤3.5 g/dL (hazard ratio [HR] 1.459), alpha-fetoprotein >20 ng/mL (HR 1.863), tumor size >2 cm but without portal hypertension or jaundice had similar prognosis to those in stages A2–A4 (all P > 0.05). The BCLC staging system provided good prognostic stratification for early-stage HCC. Patients with a single tumor >2 cm but without portal hypertension or jaundice had a similar prognosis to those in stages A2–A4. Curative therapies—aspiration biopsy for HCC—have improved, and new treatments such as transcatheter arterial chemoembolization and transarterial chemoembolization are available.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide.1–3 In most Asian and African countries, hepatitis B virus (HBV) infection is the major risk factor for HCC, while hepatitis C virus (HCV) infection is the main etiology of HCC in Japan and the West.4–5 In recent decades, the prognoses of patients with HCC have improved because more cases are diagnosed and treated at early stages due to the promotion of HCC surveillance for high-risk groups such as chronic HBV or HCV infection6–7 as well as increased application of loco-regional treatments.8–11 Important factors that may affect the prognosis of patients with HCC include patient factors (such as age and performance status),12–14 tumor burden (the size and number of tumors; vascular invasion),15 serum alpha-fetoprotein (AFP) level,16 liver functional reserve (eg, Child–Pugh score, portal hypertension...
[PHT], and platelet count),\textsuperscript{17–20} genetic factors,\textsuperscript{21–23} and treatment modalities.\textsuperscript{24,25} To date, there are more than 10 HCC-staging systems proposed by different research groups.\textsuperscript{26–29} Of these, the Barcelona Clinic Liver Cancer (BCLC) staging classification is the only validated staging system that currently links prognostic classification to appropriate treatment options. With internal and external validations, the BCLC staging system exhibits excellent prognostic stratification and is widely recommended as a treatment allocation guideline.\textsuperscript{2}

The BCLC very early stage (stage 0) includes patients with single HCC \textless 2 cm in a well-compensated liver function without PHT. The BCLC early-stage HCC (BCLC A) classification includes patients in Child–Pugh grade A or B with single HCC or with 2 or 3 nodules below 3 cm. It has been further classified into 4 subgroups (A1–A4) according to the PHT status, jaundice, and tumor numbers.\textsuperscript{26} Briefly, BCLC stage A1 consists of patients with a single tumor without PHT and jaundice. A2 is defined as a single tumor with PHT but no jaundice. BCLC stage A3 consists of single tumor with relevant PHT and increased serum bilirubin levels, and BCLC stage A4 was classified as 2 to 3 tumors smaller than 3 cm regardless of PHT or jaundice. However, there is limited data regarding the prognostic implication of substages in BCLC stage A in Asian patients. The goal of this study is to compare the clinical manifestations, treatment modalities, and outcomes between BCLC stage 0 and A1–A4 HCC patients.

METHODS

Patients and Follow-Up

This cohort study was prospectively conducted and retrospectively analyzed; it enrolled 3299 consecutive treatment-naive patients who fulfilled the diagnostic criteria of HCC by the American Association for the Study of Liver Disease (AASLD consensus, 2005).\textsuperscript{30} These were enrolled in the cancer registration system at Taipei Veterans General Hospital from October 2007 to April 2014 (Fig. 1). All of the patients were followed up every 3 months until their last visit to the hospital, death or October 31, 2014. Enrolled patients underwent thorough clinical, laboratory, and image assessment. As hepatic venous pressure gradient was not measured in our cohort, PHT was defined according to the criteria proposed by the Barcelona group for patients with the presence of either esophageal varices (EV) detectable by endoscopy and/or splenomegaly (spleen diameter >12 cm by ultrasound) with platelet counts below 100,000/mm\textsuperscript{3}.\textsuperscript{20,26} A total of 1265 BCLC stage 0 or A patients were enrolled for the final analysis after excluding patients without complete data for BCLC stage (120 patients) and those in BCLC stage B (897 patients), stage C (800 patients), and stage D (217 patients). Of these, 184 patients had BCLC stage 0, 446 patients had BCLC stage A1, 271 patients had BCLC stage A2, 92 patients had BCLC stage A3, and 272 patients had BCLC stage A4, respectively.

All of the HCC patients were discussed in terms of the diagnosis and treatment strategy at a weekly multidisciplinary meeting. The number of patients undergoing curative treatments (resection surgery and radiofrequency ablation therapy [RFA]) was 480 and 532, respectively. After the physicians explained the advantages, side effects, and prognosis in the various therapy modalities, the number of patients undergoing noncurative treatments of transarterial chemoembolization (TACE) and others (such as best supportive treatment, chemotherapy, sorafenib, radiotherapy, and chemo-radiotherapy) were 191 and 62, respectively. The study complied with the standards of the Declaration of Helsinki and current ethical guidelines. It was approved by the Institutional Review Board of Taipei Veterans General Hospital.

Biochemical and Serologic Markers

Serum hepatitis B surface antigen and the HCV antibody were tested by radio-immunoassay (Abbott Laboratories, North Chicago, IL) and second-generation enzyme immunoassay (Abbott Laboratories, North Chicago, IL). Serum biochemistries were measured using a Roche/Hitachi Modular Analytics System (Roche Diagnostics GmbH, Mannheim, Germany). The serum AFP level was tested using a radio-immunoassay kit (Serono Diagnostic SA, Coinsin/VD, Switzerland).

Statistical Analysis

The primary end point was overall survival—this was calculated from the diagnosis of HCC to death, the last patient

---

FIGURE 1. The study flow chart.
visit, or loss to follow-up. The baseline characteristics and outcomes were selected according to the European Association for the Study of the Liver guidelines from 2001.31 Fisher exact test or a Chi-squared test with Yates’ correction was used to compare categorical variables when appropriate, and the Mann–Whitney U test was used to compare continuous variables. The cumulative overall survival rates and recurrent rates after curative therapies were estimated using the Kaplan–Meier method and compared using Cox proportional hazards model.

Variables with statistical significance (P < 0.05) or approximate significance (P < 0.1) by univariate analysis were subjected to multivariate analysis using a forward stepwise logistic regression model. A 2-tailed values of P < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS 17.0 for Windows (SPSS, Inc., Chicago, IL).

RESULTS

Baseline Clinical Characteristics

The baseline demographic data are shown in Table 1 and Supplementary Table S1–S4, http://links.lww.com/MD/A488. Patients in the BCLC stage 0 group were significantly younger than those in the other groups (P = 0.001). Furthermore, patients with chronic HCV infection were more common in the BCLC A2–A4 group than those in stage 0–A1 group. Patients in the BCLC stage 0 group were significantly younger than those in the other groups (P = 0.001). Furthermore, patients with chronic HCV infection were more common in the BCLC A2–A4 group than those in stage 0–A1 group.

Liver functional reserve including total bilirubin was relatively poor for patients in the BCLC A2–A4 group (P < 0.001). They also had lower platelet counts, and higher levels of serum alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase (P < 0.001) versus other groups of patients.

The BCLC A1 group had larger tumors than the BCLC 0 or BCLC A2–A4 group. The serum AFP levels are comparable to those in other patient groups (P = 0.215). The rate of patients who underwent curative therapy was higher in the BCLC 0–A1 group versus stage A2–A4 (88.0% vs 72.2%, P < 0.001).

Overall Survival of Patients in the BCLC Stage 0 and A HCC

After a median follow-up of 21.0 (25–75 percentiles 8.9–42.1) months, 305 patients died and 960 were still alive on their last visit. When stratified by BCLC substages, the cumulative overall survival rates at 3 and 5 years were 84.9% and 72.1% in the BCLC stage 0 group; 79.5% and 65.8% in the stage A1 group; 69.6% and 48.8% in the A2 group; 52.2% and 33.2% in the A3 group; and 60.8% and 46.0% in the BCLC A4 group, respectively. As shown in Figure 2A and B, patients in the stage 0–A1 group had a significantly higher overall survival rate than those in the other substage groups (all P < 0.001). The BCLC A2 group had a significantly higher overall survival rate than the

| Parameter                          | Total (n = 1265) | Stage 0 (n = 184) | Stage A1 (n = 446) | Stage A2–A4 (635) | P     |
|------------------------------------|-----------------|-----------------|-----------------|-----------------|-------|
| Patient demographics               |                 |                 |                 |                 |       |
| Age (years) (mean ± SD)            | 65.5 ± 12.3     | 62.5 ± 12.0     | 66.2 ± 13.1     | 65.9 ± 11.6     | 0.001 |
|Sex (male), %                       | 911 (72.0)      | 134 (72.8)      | 356 (79.8)      | 421 (66.3)      | 0.001 |
| Viral factors                      |                 |                 |                 |                 |       |
| HBsAg (positive/negative)          | 611/451         | 101/50          | 220/178         | 290/223         | 0.105 |
| Anti-HCV (positive/negative)       | 424/558         | 59/75           | 119/242         | 246/241         | 0.002 |
| Serum biochemistry tests and liver function tests (continuous variables are expressed as median and 25–75 percentiles) | | | | |       |
| Albumin, g/dL                      | 3.9 ± 3.4–4.2   | 4.1 ± 3.9–4.4   | 4.1 ± 3.7–4.3   | 3.6 ± 3.2–4.0   | 0.971 |
| Total bilirubin, mg/dL             | 0.8 ± 0.5–1.1   | 0.6 ± 0.5–0.8   | 0.7 ± 0.5–0.9   | 1.0 ± 0.7–1.5   | <0.001|
| ALT, U/L                           | 40.0 ± 28.3–68.0| 36.0 ± 26.5–56.5| 37.0 ± 26.0–59.0| 45.0 ± 30.0–72.0| 0.001 |
| AST, U/L                           | 41.0 ± 28.5–68.0| 33.0 ± 24.0–49.0| 35.0 ± 25.0–54.0| 51.0 ± 34.0–80.0| <0.001|
| Creatinine, mg/dL                  | 0.9 ± 0.8–1.1   | 0.9 ± 0.8–1.0   | 0.9 ± 0.8–1.1   | 0.9 ± 0.7–1.1   | 0.718 |
| Alk-P, U/L                         | 79.0 ± 62.3–105.0| 72.0 ± 59.0–82.0| 72.0 ± 58.0–89.0| 93.5 ± 69.0–125.0| 0.001 |
| PT-INR                             | 1.1 ± 1.0–1.1   | 1.0 ± 1.0–1.1   | 1.0 ± 1.0–1.1   | 1.1 ± 1.1–1.2   | 0.618 |
| Platelet, /mm³                      | 128,000         | 163,000         | 166,000         | 60,000          | <0.001|
| Total bilirubin, mg/dL             | 84,000–177,000  | 134,000–198,500 | 137,000–203,000 | 84,000–115,250  |       |
| Tumor factors (continuous variables are expressed as median and 25–75 percentiles) | | | | |       |
| Tumor size, cm                     | 2.5 ± 1.8–3.3   | 1.6 ± 1.3–1.9   | 3.2 ± 2.6–4.0   | 2.3 ± 1.7–2.9   | <0.001|
| Single/multinodularity, %          | 1049/209        | 184/100 (100.0) | 446/100 (100.0) | 420/209         | <0.001|
| AFP, ng/mL                         | 17.3 ± 6.1–97.7 | 11.1 ± 5.5–50.4 | 13.9 ± 5.0–100.5 | 23.5 ± 8.0–100.0 | 0.215 |
| Treatment modality                 | 480/532/191/62  | 81/90/12/1      | 259/124/48/15   | 140/318/131/46  | <0.001|
| Resection/RFA/TACE/others, %       | 37.9/42.1/15.4/4.9| 44.0/48.9/6.5/0.5| 58.1/27.8/10.8/3.3| 22.0/50.2/20.6/7.2| <0.001|

AFP = alpha-fetoprotein, Alk-P = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BCLC = Barcelona Clinic Liver Cancer, HBsAg = hepatitis B surface antigen, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, PT-INR = prothrombin time-international normalized ratio, RFA = radiofrequency ablation therapy, SD = standard deviation, TACE = transarterial chemoembolization. P: comparison between BCLC 0–A1 and BCLC A2–A4 patients.
FIGURE 2. Comparison of cumulative overall survival rates stratified by BCLC substage and treatment modality. (A) Patients in the stage 0 or A1 group had a significantly higher overall survival rate than those in the other substages (all \( P < 0.001 \)). BCLC 0 versus A1 (\( P = 0.136 \)) had comparable overall survival rates. (B) The overall survival rates were higher in the BCLC stage 0–A1 group than that in the BCLC stage A2–A4 group (\( P < 0.001 \)). (C) Patients who underwent resection surgery had the highest overall survival rates than the other groups (all \( P < 0.001 \)). (D) For patients in BCLC stage 0–A1 group, RFA and resection had comparable overall survival rates (\( P = 0.465 \)); both of them were significantly better than other treatment modalities. (E) For patients in BCLC stage A2–A4, patients who underwent resection had the highest overall survival rates than other treatment modalities including RFA. BCLC = Barcelona Clinic Liver Cancer, RFA = radiofrequency ablation therapy.
BCLC A3 group (P = 0.019). The BCLC 0 versus A1 (P = 0.136), A2 versus A4 (P = 0.142), and BCLC A3 versus A4 (P = 0.206) had comparable overall survival rates.

Stratified by the treatment modalities, patients who underwent resection surgery had the highest overall survival rate versus other therapies followed by RFA, TACE, and other therapies (Fig. 2C). All of the treatment modalities showed significantly different overall survival statistics.

**Multivariate Analysis of Independent Risk Factors Associated With Poor Prognosis**

As the substages of BCLC stage A are classified by PHT and jaundice, we applied 2 multivariate analysis models to minimize the potential confounding effects of these parameters. In model I, the BCLC stage was enrolled, but platelet count and bilirubin levels were not entered into the multivariate analysis. In model II, we selected platelets and bilirubin, but not BCLC stage for multivariate analysis.

In model I, serum albumin levels ≤3.5 g/dL (P = 0.009), AFP >20 ng/mL (P < 0.001), tumor size >3 cm (P = 0.003), BCLC stage A2–A4 (P = 0.013), and treatment modality (resection as reference, RFA, hazard ratio, HR 1.598, 95% confidence interval CI: 1.142–2.237, and P = 0.006; TACE, HR 2.224, 95% CI: 1.507–3.282, and P < 0.001; and others, HR 3.707, 95% CI: 2.076–6.620, and P < 0.001) were the independent risk factors associated with poor overall survival (Table 2).

In model II, serum bilirubin levels >1.6 g/dL (HR 1.540, 95% CI: 1.080–2.20; and P = 0.007), platelet ≤10^5/mm^3 (HR 1.362, 95% CI: 1.012–1.833, and P = 0.042), AFP >20 ng/mL (HR 1.949, 95% CI: 1.491–2.549, and P < 0.001), tumor size >3 cm (HR 1.508, 95% CI: 1.143–1.989, and P = 0.004), and treatment modality (RFA, HR 1.709, 95% CI: 1.223–2.389, and P = 0.002; TACE, HR 2.391, 95% CI: 1.619–3.530, P < 0.001; and others, HR 4.138, 95% CI: 2.329–7.352, and P < 0.001) were the independent risk factors associated with poor overall survival.

**Prognoses of Patients in the BCLC Stage 0–A1 HCC**

The prognoses were significantly better in patients who had tumors in stage 0–A1, and we further assessed these patients for prognostic factors. Of the 630 patients in BCLC stage 0–A1, 340 underwent resection, 214 patients received RFA, 60 patients underwent TACE, and the remaining 16 patients received other therapies.

As shown in Table 3 and Figure 2D, multivariate analysis showed that serum albumin ≤3.5 g/dL (P = 0.005), AFP >20 ng/mL (P = 0.012), tumor size >3 cm (P = 0.028), and treatment modalities (resection as reference, RFA, P = 0.109; TACE, and P = 0.035; and other therapies, P = 0.012) were the independent risk factors predicting poor prognoses in BCLC stage 0 or A1 patients.

**Prognoses of Patients in the BCLC Stage A2–A4 HCC**

Of the 635 patients in BCLC stage A2–A4, the number of patients undergoing resection, RFA, TACE, and other therapies were 140, 318, 131, and 46, respectively. Multivariate analysis

---

**TABLE 2. Factors Associated With Poor Overall Survival in BCLC Stage 0 and A HCC Patients in Model I**

| Variable                  | Case No. | Univariate Analysis | Multivariate Analysis |
|---------------------------|----------|---------------------|-----------------------|
| Age >65/≤65 y/o *         | 648/617  | 1.429 (1.139–1.794) | 0.002                 |
| Sex/female/male           | 354/911  | 1.094 (0.849–1.409) | 0.487                 |
| HBSAg positive/negative   | 611/451  | 1.008 (0.890–1.140) | 0.902                 |
| Anti-HCV positive/negative| 424/558  | 0.974 (0.881–1.076) | 0.602                 |
| Albumin ≤3.5/3.5 g/dL *   | 371/856  | 2.169 (1.725–2.728) | <0.001                |
| Bilirubin >1.6/1.6 mg/dL *| 147/1098 | 2.317 (1.742–3.083) | <0.001                |
| ALT >40/≤40 U/L           | 622/631  | 0.998 (0.796–1.251) | 0.986                 |
| Alk-P >100/≤100 U/L *     | 253/647  | 1.021 (1.008–1.034) | 0.001                 |
| Platelet ≤10^5/10^5/mm^3 *| 436/818  | 2.093 (1.671–2.621) | <0.001                |
| PT-INR >1.1/1.1 *         | 419/825  | 1.943 (1.458–2.328) | <0.001                |
| Portal hypertension (yes/no)* | 489/776 | 2.276 (1.814–2.854) | <0.001                |
| AFP >20/≤20 ng/mL *       | 585/645  | 2.022 (1.600–2.555) | <0.001                |
| Multiple tumor (yes/no)*  | 209/1049 | 1.491 (1.127–1.972) | 0.005                 |
| Tumor size >3 cm/≤3 cm *  | 357/897  | 1.244 (0.980–1.579) | 0.073                 |
| BCLC (A2–A4/A0/A1) *      | 635/630  | 2.276 (1.794–2.888) | <0.001                |
| Treatment modality *      | 480      | 1                   |                       |
| RFA                       | 532      | 1.769 (1.337–2.340) | <0.001                |
| TACE                      | 191      | 3.000 (2.164–4.159) | <0.001                |
| Others                    | 62       | 5.564 (3.422–9.047) | <0.001                |

AFP = alpha-fetoprotein, Alk-P = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate Aminotransferase, BCLC = Barcelona Clinic Liver Cancer, CI = confidence interval, HBSAg = hepatitis B surface antigen, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, PT-INR = prothrombin time-international normalized ratio, RFA = radiofrequency ablation therapy, TACE = transarterial chemoembolization.

* Parameters that were subjected to multivariate analysis.

---

**Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal.com | 5**
Factors Associated With Poor Overall Survival in BCLC Stage 0 or A1 HCC Patients

**TABLE 3.**

| Variable                              | Case No. | Univariate Analysis | Multivariate Analysis |
|---------------------------------------|----------|---------------------|-----------------------|
| Age >65/≤65 y/o                        | 325/305  | 1.213 (0.821–1.794) | 0.332                 |
| Sex female/male                       | 140/490  | 0.902 (0.642–1.302) | 0.692                 |
| HBsAg positive/negative               | 321/228  | 0.979 (0.829–1.150) | 0.975                 |
| Anti-HCV positive/negative*           | 178/317  | 0.891 (0.790–1.006) | 0.062                 |
| Albumin ≤3.5/≤3.5 g/dL*               | 92/519   | 2.293 (1.456–3.611) | <0.001                |
| ALT >40/≤40 U/L                       | 273/353  | 0.914 (0.618–1.352) | 0.652                 |
| Alk-P >100/≤100 U/L                   | 74/393   | 1.000 (0.972–1.029) | 0.979                 |
| PT-INR >1.1/≤1.1                      | 101/517  | 1.026 (0.852–1.289) | 0.929                 |
| AFP >20/≤20 ng/mL*                    | 257/356  | 1.810 (1.223–2.679) | 0.003                 |
| Tumor size >3 cm/≤3 cm*               | 244/385  | 1.730 (1.173–2.554) | 0.006                 |
| Treatment modality*                   |          |                     |                       |
| Resection                             | 340      | 1.174 (0.761–1.809) | 0.465                 |
| RFA                                   | 214      | 2.155 (1.188–3.909) | 0.011                 |
| TACE                                  | 60       | 5.579 (1.719–18.113) | 0.003                 |
| Others                                | 16       | 4.553 (1.391–14.920) | 0.012                 |

**AFP** = alpha-fetoprotein, **Alk-P** = alkaline phosphatase, **ALT** = alanine aminotransferase, **AST** = aspartate aminotransferase, **BCLC** = Barcelona Clinic Liver Cancer, **CI** = confidence interval, **HBsAg** = hepatitis B surface antigen, **HCC** = hepatocellular carcinoma, **HCV** = hepatitis C virus, **PT-INR** = prothrombin time-international normalized ratio, **RFA** = radiofrequency ablation therapy, **TACE** = transarterial chemoembolization.

*Parameters that were subjected to multivariate analysis.

Comparison of Prognosis Among Different BCLC Substages Stratified by Treatment Modalities

Subsequently, we assessed the effect of the same treatment modality in determining the prognosis of patients among different BCLC substages. For those who underwent resection

Factors Associated With Poor Overall Survival in BCLC Stage A2–A4 HCC Patients

**TABLE 4.**

| Variable                              | Case No. | Univariate Analysis | Multivariate Analysis |
|---------------------------------------|----------|---------------------|-----------------------|
| Age >65/≤65 y/o*                      | 323/312  | 1.604 (1.212–2.122) | 0.001                 |
| Sex female/male                       | 214/421  | 0.988 (0.734–1.328) | 0.934                 |
| HBsAg positive/negative               | 290/223  | 1.014 (0.854–1.204) | 0.868                 |
| Anti-HCV positive/negative*           | 246/241  | 1.019 (0.874–1.189) | 0.805                 |
| Albumin ≤3.5/≤3.5 g/dL*               | 279/336  | 1.583 (1.198–2.093) | 0.001                 |
| Bilirubin >1.6/≤1.6 mg/dL*            | 147/477  | 1.656 (1.221–2.496) | 0.001                 |
| ALT >40/≤40 U/L                       | 349/278  | 0.921 (0.696–1.217) | 0.561                 |
| Alk-P >100/≤100 U/L*                  | 179/254  | 1.015 (0.999–1.030) | 0.038                 |
| PT-INR >1.1/≤1.1*                     | 318/308  | 1.604 (1.205–2.137) | 0.001                 |
| Portal hypertension (yes/no)*         | 489/146  | 1.591 (1.080–2.344) | 0.019                 |
| AFP >20/≤20 ng/mL*                    | 328/289  | 1.896 (1.413–2.456) | <0.001                |
| Multiple tumor (yes/no)               | 209/420  | 0.980 (0.727–1.322) | 0.895                 |
| Tumor size >3 cm/≤3 cm*               | 113/512  | 1.515 (1.096–2.096) | 0.012                 |
| Treatment modality*                   |          |                     |                       |
| Resection                             | 140      | 1                   |                       |
| RFA                                   | 318      | 1.796 (1.168–2.761) | 0.006                 |
| TACE                                  | 131      | 2.738 (1.715–4.372) | <0.001                |
| Others                                | 46       | 4.388 (2.397–8.033) | <0.001                |

**AFP** = alpha-fetoprotein, **Alk-P** = alkaline phosphatase, **ALT** = alanine aminotransferase, **AST** = aspartate aminotransferase, **BCLC** = Barcelona Clinic Liver Cancer, **CI** = confidence interval, **HBsAg** = hepatitis B surface antigen, **HCC** = hepatocellular carcinoma, **HCV** = hepatitis C virus, **PT-INR** = prothrombin time-international normalized ratio, **RFA** = radiofrequency ablation therapy, **TACE** = transarterial chemoembolization.

*Parameters that were subjected to multivariate analysis.
surgery, patients in the stage 0–A1 group had a comparable overall survival rate with those in the stage A2–A4 (P = 0.148). In the RFA group, patients in the stage 0–A1 group had a significantly higher overall survival rate than those in the stage A2–A4 (P < 0.001). In the TACE group, patients in the stage 0–A1 group had a higher overall survival rate than those in the stage A2–A4 (P = 0.035). For those underwent other therapy modalities, patients in the stage 0–A1 group had a comparable overall survival rate with their counterpart (P = 0.399). BCLC = Barcelona Clinic Liver Cancer, RFA = radiofrequency ablation therapy, TACE = transarterial chemoembolization.

Comparison of Resection Surgery and RFA Stratified by BCLC Substages

We next compared the treatment efficacy between resection surgery and RFA in these patients. The cumulative overall survival rates at 3 and 5 years were 82.4% and 70.4% in the resection surgery group and 80.2% and 68.1% in the RFA group, respectively (Figure 4A, P = 0.001). Moreover, the cumulative recurrence rates at 3 and 5 years were 39.2% and 53.9% in the resection surgery group; and 55.0% and 62.3% in the RFA group, respectively (Figure 4B, P < 0.001).

In the BCLC stage 0–A1 group, the cumulative overall survival rates at 3 and 5 years were 84.4% and 70.7% in the resection surgery group and 80.2% and 68.1% in the RFA group, respectively (Figure 4C, P = 0.035). Moreover, the cumulative recurrence rates at 3 and 5 years were 35.3% and 48.7% in the resection surgery group; and 45.8% and 53.4% in the RFA group, respectively (Figure 4D, P = 0.085). This suggested that although they had similar overall survival rates, patients who underwent resection surgery had a trend of lower incidence of recurring than those treated by RFA in patients with BCLC stage 0 or A1.

For patients in BCLC stage A2–A4, the cumulative overall survival rates at 3 and 5 years were 77.0% and 69.2% in the resection surgery group, 65.6% and 43.6% in the RFA group, respectively (Figure 4E, P = 0.006). Moreover, the cumulative recurrence rates at 3 and 5 years were 39.2% and 53.9% in the resection surgery group; and 55.0% and 62.3% in the RFA group, respectively (Figure 4F, P = 0.001).
FIGURE 4. Comparison of overall survival and recurrence rates between RFA and resection surgery for HCC stratified by BCLC substage. In a total cohort, patients who underwent resection had a higher overall survival rate (A, \( P < 0.001 \)) and lower rate of recurrence (B, \( P < 0.001 \)) versus those receiving RFA. For BCLC stage 0–A1 HCC patients, there was no statistical significance between RFA and resection in overall survival (C, \( P = 0.465 \)); resection did have a trend of lower incidence of recurrence versus RFA (D, \( P = 0.085 \)). Among the BCLC stage A2–A4 patients, the resection group had a better prognosis than the RFA group both in terms of overall survival (E, \( P = 0.006 \)) and recurrence (F, \( P = 0.045 \)). BCLC = Barcelona Clinic Liver Cancer, HCC = hepatocellular carcinoma, RFA = radiofrequency ablation therapy.
recurrence rates at 3 and 5 years were 46.0% and 68.7% in the resection surgery group, 61.1% and 68.5% in the RFA group, respectively (Fig. 4F, $P = 0.045$). Patients who underwent resection surgery had better prognoses than those receiving RFA both in terms of overall survival and recurrence.

**DISCUSSION**

The BCLC staging system is a prognostic system and offers guidance for treatment decisions based on tumor burden, liver functional reserve, and performance status.1,2 There are several major findings in this study. First, we demonstrated that the substages of early-stage HCC provided a good prediction for prognosis. Second, patients in BCLC stage 0–A1 had higher chances of undergoing curative therapy. They also had similar prognoses and were significantly better than those in the stages A2–A4. Third, patients who underwent surgical resection had a higher overall survival rate than those receiving other treatment modalities. This result suggests that curative therapies, especially hepatic resection, should be performed in early-stage HCC.32,33

In this study, patients in BCLC stages 0 and A1 had comparable prognoses ($P = 0.136$). Both of them had significantly higher overall survival rates than those in stages A2–A4 (all $P < 0.001$). Furthermore, patients in BCLC stages A2 and A4 had similar overall survival rates ($P = 0.142$), BCLC stage A3 had the worst outcome due to both increased bilirubin and clinically significantly elevated PHT. This implied that BCLC stage A patients are not all the same. This heterogeneity may have an impact on survival.

In our cohort, the cumulative survival rate 5 years after resection was 70.7% for the best candidates who had single HCC without PHT and with normal serum bilirubin levels. This was consistent with the findings of the BCLC staging system proposed by Professor Bruix and Llovet in 1999. They reported that the cumulative 5-year survival rate after resection surgery was 74%.26 We also demonstrate that serum albumin and AFP levels, tumor size, BCLC substage, and treatment modalities are strong predictors of outcome. This is consistent with the results from previous studies including both tumor factors (tumor size, number, vascular invasion, tumor cell differentiation, etc.) and field factors (grade of hepatic inflammation, stage of fibrosis, PHT, liver functional reserve, viral replication, etc.) that have been shown to influence the prognosis of HCC patients.1,8,34–36

Assessment of liver functional reserve is critical for the management of HCC because cirrhosis is a competing cause of death. For patients with early-stage HCC, field factors play more important roles than advanced tumor stages. The substages of early-stage HCC are classified by PHT, jaundice, and number of tumors.26 This stratification arises from studies on the BCLC groups that reported that PHT and increased serum bilirubin levels are independent predictors of an elevated risk of PHT. This implied that BCLC stage A patients are not all the same. This heterogeneity may have an impact on survival.

PHT is a hepatic-vein pressure gradient more than 5 mmHg. Clinically significant PHT is indicated when the hepatic-vein pressure gradient is above 10 mmHg—this is also the threshold for development of gastroesophageal varices.37 A large study of Italian patients with HCC showed that the prevalence of EV in patients with HCC is around 60% to 80%.38 Of note, HCC patients with EV are associated with a significantly poorer prognosis than those without EV.

Serum albumin and bilirubin levels are the 2 most significant independent prognostic factors to predict hepatic events in patients with cirrhosis.37 A new prognostic score, the albumin–bilirubin (ALBI) score, which incorporates serum albumin and bilirubin concentrations, can offer an evidence-based, objective, and discriminatory method of assessing liver function with good prognostic performance in HCC.39 In our cohort, when assessing the independent risk factors predicting poor overall survival by multivariate analysis, model I demonstrated that BCLC stage is correlated to poor prognosis. In model II, when the BCLC substage is not enrolled, its 2 major determinants (platelet count and serum bilirubin level) could predict outcomes. This validated the critical role of the BCLC substages in determining the prognoses of Asian patients with early-stage HCC.

Curative therapies including surgical resection, local ablation therapies, and liver transplantation are recommended as first-line treatment modalities in early-stage HCC patients.1,2 Of the curative therapies, liver transplantation is limited by organ donor shortage. Resection surgery and RFA are the major therapies in daily Taiwanese practice.24 Treatment modalities are related to long-term outcomes and are an independent predictor of HCC patient prognosis.14,27 However, underutilization of curative treatments for early-stage HCC is not uncommon due to tumor factors, performance status, and availability of treatment modalities.32,40,41

In this study, 80.0% of the early-stage HCC patients received curative treatment, but this is still not good enough. To better match the treatment modality with the BCLC staging system guidelines in the real world, a multidisciplinary HCC team approach may help physicians and encourage patients to choose the optimal curative treatment modalities.

The efficacy of RFA with surgical resection in the treatment of early-stage HCC is still actively debated.26–42 In this study, surgical resection provides better prognoses both in long-term overall survival and in recurrence versus RFA in patients with early-stage HCC. The superiority of resection was more apparent in BCLC stage A2–A4, which considered PHT or tumor number. Moreover, the overall survival rates were comparable between BCLC stage 0–A1 and A2–A4 in patients who underwent resection surgery (Fig. 3). Consequently, our study also confirms that neither PHT nor multinodular tumors are contra-indicated for resection surgery.44–46 This provides a more favorable outcome than other treatment modalities and is therefore recommended for such patients if there is no contraindication for operation.

The role of viral factors in HCC prognosis remains controversial.4,35,47–49 In this study, patients with chronic HCV infection had a higher recurrence rate than their counterparts. Previous studies showed that in early-stage HCC, patients with HBV infection had better prognosis than those with HCV due to better liver reserve and less hepatic fibrosis.50 Furthermore, our previous study demonstrated that HCV-related HCC correlated with overexpression of twist, a major regulator of epithelial–mesenchymal transition that is critical for the induction of invasiveness and metastasis for human cancers.50,51 There are some limitations to this study. First, our study included HCC patients from a single tertiary center. Second, interobserver bias may exist in the amount of ascites and the degree of hepatic encephalopathy for Child–Pugh scoring—this is an important parameter of BCLC staging. Third, our cohort did not include any HCC patients who underwent liver transplantation as an initial treatment modality. Thus, this data may not be relevant to medical centers that perform many liver transplants. Fourth, we could not assess the effect of the same treatment modality in determining the prognosis of HCC.
patients in each BCLC substage due to relatively small number of patients in some substages. Further large-scale prospective studies are needed to elucidate this issue.

CONCLUSIONS

The substages of the BCLC staging system based on PHT, serum bilirubin levels, and tumor numbers was useful in predicting survival in patients with early-stage HCC. Patients with single tumor larger than 2 cm but without significant PHT or jaundice had similar prognosis to those in BCLC stage 0. Moreover, curative therapies, especially hepatic resection, were crucial in determining the prognosis and should be performed in early-stage HCC.

ACKNOWLEDGEMENTS

The authors thank Pui-Ching Lee for her assistance with the statistical analysis. The author also thank American Manuscript Editors for English editing and writing assistance. This work was supported by grants from the National Science Council of Taiwan (NSC 101-2314-B-075-013-MY2), Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program (104-V-B-031), and partly from a grant from Ministry of Education, Aim for the Top University Plan (103AC-T402), and the Center of Excellence for Cancer Research at TVGH (MOHW104-TDU-B-211-124-001), Taipei, Taiwan. All authors approved the final version of the article, including the authorship list.

REFERENCES

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.
4. Chen PH, Kao WY, Chou YY, et al. Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Ann Surg. 2013;12:263–273.
5. Su CW, Wu CY, Hung HH, et al. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy. J Gastroenterol Hepatol. 2013;28:1849–1858.
6. Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2012;56:397–405.
7. Altekruse SF, McGlynn KA, Dickie LA, et al. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology. 2012;55:476–482.
8. Shinya S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107:569–577.
9. Kim YS, Lim HK, Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58:89–97.
10. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:43–58.
11. Mazzaferro V, Lencioni R, Majno P. Early hepatocellular carcinoma on the preoperative bed of ablation, resection, and transplantation. Semin Liver Dis. 2014;34:415–426.
30. Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology*. 2005;42:1208–1236.
31. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. *J Hepatol*. 2001;35:421–430.
32. D’Avola D, Inarrairaegui M, Pardo F, et al. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. *Ann Surg Oncol*. 2011;18:617–624.
33. Vitale A, Burra P, Frigo AC, et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. *J Hepatol*. 2009;51:890–897.
34. Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. *J Hepatol*. 2009;51:890–897.
35. Kao WY, Su CW, Chau GY, et al. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. *World J Surg*. 2011;35:858–867.
36. Hung HH, Su CW, Lai CR, et al. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. *Hepatol Int*. 2010;4:691–699.
37. Tuohatziea EA, Boscoh J, Burroughs AK. Liver cirrhosis. *Lancet*. 2014;383:1749–1761.
38. Giannini EG, Risso D, Testa R, et al. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. *Clin Gastroenterol Hepatol*. 2006;4:1378–1384.
39. Johnson PJ, Berhane S, Kageyashic C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. *J Clin Oncol*. 2015;33:550–558.
40. Kim BK, Kim SU, Park JY, et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naive patients with hepatocellular carcinoma. *Liver Int*. 2012;32:1120–1127.
41. Tan D, Yopp A, Beg MS, et al. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. *Aliment Pharmacol Ther*. 2013;38:703–712.
42. Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg*. 2010;252:903–912.
43. Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. *J Hepatol*. 2013;58:724–729.
44. Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. *Ann Surg*. 2013;257:929–937.
45. Kluger MD, Salceda JA, Laurent A, et al. Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis. *J Hepatol*. 2015;62:1131–1140.
46. Cucchetti A, Ercolani G, Vivarelli M, et al. Is portal hypertension a contraindication to hepatic resection? *Ann Surg*. 2009;250:922–928.
47. Sinn DH, Gwak GY, Cho J, et al. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. *PLoS One*. 2014;9:e112184.
48. Su CW, Chou YW, Tsai YH, et al. The influence of hepatitis B viral load and pre-S deletion mutations on post-operative recurrence of hepatocellular carcinoma and the tertiary preventive effects by anti-viral therapy. *PLoS One*. 2013;8:e66457.
49. Huang YH, Wu JC, Chen CH, et al. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. *Liver Int*. 2005;25:236–241.
50. Yang MH, Chen CL, Chau CY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. *Hepatology*. 2009;50:1464–1474.